|Bid||285.50 x 800|
|Ask||290.00 x 800|
|Day's Range||284.28 - 289.58|
|52 Week Range||244.28 - 370.57|
|PE Ratio (TTM)||20.46|
|Earnings Date||Jul 23, 2018 - Jul 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||350.04|
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) to $144.4 million from $145.3 million. Analysts expect its revenue to grow 30.2% YoY to $135.7 million in the second quarter. The graph below compares Ionis’s revenue since Q1 2017.
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.
A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.
Nine drug developers based in Massachusetts have now gone public in the first half of 2018, raising a total of $910 million. By comparison, 12 local biotechs held IPOs in all of last year, generating around $1 billion in proceeds.
You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result. Some of the big pharma stocks were able to replace that revenue and some weren’t.
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.
Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.
On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.
BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.
South Korean drugmaker Samsung BioLogics said on Friday joint venture partner Biogen would exercise its call option to increase its stake to 50 percent minus one share in Samsung Bioepis. The plan comes as BioLogics is mired in a regulatory probe into its accounting rules. South Korea's financial regulator said it notified BioLogics, an affiliate of tech giant Samsung Electronics , of measures it could take concerning any breach of accounting rules.
The FDA’s decision to publish a list of companies accused of blocking access to their product samples is part of a broader effort by the Trump administration to address high drug costs.
President Donald Trump’s new plan, “American Patients First,” is supposed to make U.S. drug prices cheaper. For some players, there could be long-term concerns, including for pharmacy-benefit managers and other drug system middlemen. This was partly because many of the ideas in the plan had been raised by the Trump administration prior to the speech, including in a proposed 2019 budget.
Today I will examine Biogen Inc’s (NASDAQ:BIIB) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, in addition to howRead More...
Stocks that moved substantially or traded heavily on Friday: Symantec Corp., down $9.66 to $19.52 The security software maker gave weak forecasts and disclosed an internal investigation. Yelp Inc., down ...
The biotech group is trying to climb past its 50-day moving average, so it may be a good time to keep an eye on biotech ETFs.
In this daily bar chart, below, we can see that BIIB has rallied above the bottoming 50-day moving average line. The daily On-Balance-Volume (OBV) line has been moving sideways since early March even though prices were still declining into late April. In the bottom panel of this chart we can see a bullish divergence as momentum makes higher lows from February while prices made lower lows.
Jim Cramer examines "the four horsemen of biotech" to see if their weakening stocks can regain momentum.